Illinois-based Nanosphere, Inc. has reportedly closed a public offering of more than 17 million shares of common stock at $1.75 per share, including 2,250,000 shares that were part of an over-allotment option exercised in full by the underwriters. The company’s Verigene® System uses proprietary gold nanoparticle chemistry to achieve “highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing.” The system can apparently detect infectious pathogens and drug resistance markers by mapping bacterium genomes. The company, which will use the net proceeds of the sale for general corporate purposes and working capital, currently employs Verigene® to target infections of the bloodstream and respiratory and gastrointestinal tracts.See Nanosphere, Inc. Press Release, September 18, 2013.